The dark skin pigment melanin protects us from the sun’s damaging rays by absorbing light energy and converting it to heat. This could make it a very effective tool in tumor diagnosis and treatment, as demonstrated by a team from the Technical University of Munich (TUM) and Helmholtz Zentrum München. The scientists managed to create melanin-loaded cell membrane derived nanoparticles, which improved tumor imaging in an animal model while also slowing the growth of the tumor.
Nanoparticles are considered a promising weapon in the fight against tumors due to the fact that tumor tissue absorbs them more readily than healthy cells because their vascular system is more permeable. A good example is provided by outer membrane vesicles (OMVs), which are basically small bubbles surrounded by bacterial membrane. These 20- to 200-nanometer particles are of interest because they are biocompatible, biodegradable and can be easily and inexpensively produced in bacteria, even in large volumes. Once loaded with medicinal active agents, they are easy to administer.
NANOPARTICLES CARRYING A BLACK CARGO
The huge potential of OMVs in tumor diagnosis and treatment has been demonstrated by Prof. Vasilis Ntziachristos, Professor of Biological Imaging at TUM, and his team. Their work builds on the characteristic properties of OMVs and melanin.’
Dr. Vipul Gujrati, first author of the study, explains the principle: “Melanin absorbs light very readily – even in the infrared spectrum. We use precisely this light in our optoacoustic imaging technique for tumor diagnosis. It simultaneously converts this absorbed energy into heat, which is then emitted. Heat is also a way to combat tumors – other researchers are currently exploring this method in clinical trials.”
Optoacoustics, a method which has been significantly advanced by Ntziachristos, combines the benefits of optical imaging and ultrasound technology. Weak laser pulses gently heat the tissue, causing it to briefly expand very slightly. Ultrasound signals are produced when the tissue contracts again as it cools down. The measured signals vary depending on the tissue type. The scientists record them with special detectors and “translate” them into three-dimensional images. Sensor molecules or probes (such as OMVs) can improve the specificity and accuracy of the technique even further.
HEAT BUILD-UP REDUCES TUMOR GROWTH
The scientists initially had to overcome a problem specific to melanin: It is not very water-soluble and therefore difficult to administer. This is where the OMVs came into play. The researchers engineered bacteria in such a way that they produce melanin and store it in their membrane derived nanoparticles. They then tested the black nanoparticles in mice which had tumors in their lower back region. The particles were injected directly into the tumor, which was excited with infrared laser pulses as part of the optoacoustic procedure.
OMVs proved to be suitable sensor probes for this diagnosis technique because they delivered sharp, high-contrast images of the tumor. They are also well-suited to photothermal therapy approaches, where the tumor tissue is heated with stronger laser pulses in order to kill the cancer cells. The melanin in the nanoparticles caused the temperature of the tumor tissue to rise from 37 °C to up to 56 °C. Control tumors with no melanin only reached a maximum temperature of 39 °C. In the ten days following the treatment, the tumors grew at a significantly slower rate than those in the control group that had not received melanin OMVs. This heat effect was amplified by another positive effect of the particles: By causing a slight non-specific inflammation in the tumor tissue, the immune system was triggered to attack the tumor.
“Our melanin nanoparticles fit into the new medical field of theranostics – where therapy and diagnostics are combined. This makes them a highly interesting option for use in clinical practice,” says Ntziachristos. The scientists will now develop their OMVs further to bring them into clinical use in the future.
Learn more: Black nanoparticles slow the growth of tumors
The Latest on: Theranostics
via Google News
The Latest on: Theranostics
- 2020 Prostate Cancer - Thomas Hope (Bringing PSMA PET-CT to the US) - 1944on January 18, 2021 at 9:40 pm
We're going to have a conversation today about what that journey has been like and the future of PSMA-PET, and other molecular imaging for prostate cancer. So Tom, welcome. Thomas Hope: Great. Thank ...
- THERADIAG Signs a Contract to Supply ORGENTEC With Quality Control Reagents Called Alegria® Checkon January 14, 2021 at 1:45 pm
Regulatory News: THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today a ...
- Astellas signs research collaboration with Actinium Pharma for molecular targeted radiotherapyon January 14, 2021 at 2:30 am
Astellas signs research collaboration with Actinium Pharma for molecular targeted radiotherapy: Tokyo Thursday, January 14, 2021, 16:00 Hrs [IST] Astellas Pharma Inc has entered i ...
- Theranostics Market to grow at a CAGR of 11.4% by 2025 | Global Size By Top Leaders, Trends, Growth, Report and Forecaston January 12, 2021 at 6:50 am
Market Highlights The global theranostics market size accounted for USD 7,968.4 million in 2018 and is projected to grow at ...
- THERADIAG Announces CE Marking for Four New i-Tracker® Test Kits for Biotherapy Monitoringon January 11, 2021 at 2:45 am
THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER) , a company specializing in in vitro diagnostics and theranostics, today announces that it has obtained CE marking for four additional ...
- Advancements in Theranostics from Diagnosis to Treatment in Advanced Prostate Canceron January 6, 2021 at 4:00 pm
Resistant Prostate Cancer - The VISION Trial: Oliver Sartor joins Charles Ryan to talk about the VISION trial, a trial testing the ...
- Prostate Cancer | Tumoron December 17, 2020 at 4:01 pm
While the current field of prostate cancer research is experiencing an era of “warp speed developments,” perhaps the most exciting option on the horizon is theranostics, according to Dr. Phillip J.
- Clinical Study That Meets French National Authority for Health Requirements Highlights the Quality of the Tests Marketed by Theradiagon December 13, 2020 at 11:52 pm
THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER), a company specializing in in vitro diagnostics and theranostics, announces the publication of a study that meets French National ...
- Theranostics in Primary Careon December 12, 2020 at 4:00 pm
In addition to PGx, theranostics applications include the use of genomics platforms with, for example, nutrition (nutrigenomics), development of vaccines (vaccinomics) and diagnostics ...
- Theranostics Market Analytical Overview, Growth Factors, Demand, Trends and Forecast to 2026on November 25, 2020 at 2:16 pm
Nov 25, 2020 (Market Insight Reports) -- Selbyville, Delaware. A Research study on Theranostics Market analyzes and offers ideas of exhaustive research on ancient and recent Theranostics market size.
via Bing News